523 related articles for article (PubMed ID: 30667343)
1. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model.
Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY
Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343
[TBL] [Abstract][Full Text] [Related]
2. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
[TBL] [Abstract][Full Text] [Related]
3. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
6. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
[TBL] [Abstract][Full Text] [Related]
7. Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells.
Lin X; Li JJ; Qian WJ; Zhang QJ; Wang ZF; Lu YQ; Dong EL; He J; Wang N; Ma LX; Chen WJ
Oncotarget; 2017 Jun; 8(26):42030-42042. PubMed ID: 28159932
[TBL] [Abstract][Full Text] [Related]
8. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
[TBL] [Abstract][Full Text] [Related]
9. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.
Naryshkin NA; Weetall M; Dakka A; Narasimhan J; Zhao X; Feng Z; Ling KK; Karp GM; Qi H; Woll MG; Chen G; Zhang N; Gabbeta V; Vazirani P; Bhattacharyya A; Furia B; Risher N; Sheedy J; Kong R; Ma J; Turpoff A; Lee CS; Zhang X; Moon YC; Trifillis P; Welch EM; Colacino JM; Babiak J; Almstead NG; Peltz SW; Eng LA; Chen KS; Mull JL; Lynes MS; Rubin LL; Fontoura P; Santarelli L; Haehnke D; McCarthy KD; Schmucki R; Ebeling M; Sivaramakrishnan M; Ko CP; Paushkin SV; Ratni H; Gerlach I; Ghosh A; Metzger F
Science; 2014 Aug; 345(6197):688-93. PubMed ID: 25104390
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
11. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.
Bebee TW; Dominguez CE; Samadzadeh-Tarighat S; Akehurst KL; Chandler DS
Hum Mol Genet; 2012 Oct; 21(19):4301-13. PubMed ID: 22763238
[TBL] [Abstract][Full Text] [Related]
13. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
Kannan A; Jiang X; He L; Ahmad S; Gangwani L
Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
[TBL] [Abstract][Full Text] [Related]
14. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice.
Hsu YY; Jong YJ; Tsai HH; Tseng YT; An LM; Lo YC
Br J Pharmacol; 2012 Jun; 166(3):1114-26. PubMed ID: 22220673
[TBL] [Abstract][Full Text] [Related]
15. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
[TBL] [Abstract][Full Text] [Related]
16. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.
Mattis VB; Butchbach ME; Lorson CL
J Neurosci Methods; 2008 Oct; 175(1):36-43. PubMed ID: 18771690
[TBL] [Abstract][Full Text] [Related]
17. Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
Ratni H; Karp GM; Weetall M; Naryshkin NA; Paushkin SV; Chen KS; McCarthy KD; Qi H; Turpoff A; Woll MG; Zhang X; Zhang N; Yang T; Dakka A; Vazirani P; Zhao X; Pinard E; Green L; David-Pierson P; Tuerck D; Poirier A; Muster W; Kirchner S; Mueller L; Gerlach I; Metzger F
J Med Chem; 2016 Jul; 59(13):6086-100. PubMed ID: 27299419
[TBL] [Abstract][Full Text] [Related]
18. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.
Riessland M; Brichta L; Hahnen E; Wirth B
Hum Genet; 2006 Aug; 120(1):101-10. PubMed ID: 16724231
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
[TBL] [Abstract][Full Text] [Related]
20. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Garbes L; Riessland M; Hölker I; Heller R; Hauke J; Tränkle C; Coras R; Blümcke I; Hahnen E; Wirth B
Hum Mol Genet; 2009 Oct; 18(19):3645-58. PubMed ID: 19584083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
